Companies: 10,795·Total market cap: $144.5T
XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd.

XTLBNASDAQHealthcare● Active
$2.29
+$0.06(+2.69%)
Market Cap$5417240
P/E Ratio—
52W High$10.28
52W Low$2.02
Shares OutstandingFinancialsRevenue

XTL Biopharmaceuticals Ltd. (XTLB) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

XTLB · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
105,163▲ +23.50% YoY Change
FY · as of Dec 31, 2024 · Reported in USD
vs 85,149 in FY 2023
Diluted Shares Outstanding
110,025
incl. options, RSUs, convertibles
Dilution Spread
+4.62%
Diluted vs Basic
YoY Change
+23.50%
year-over-year
Float (Free Float)
2.3M
publicly tradable shares
97.5% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+8.2%
2021 → 2024
5-Year CAGRincreasing
+5.5%
2019 → 2024
10-Year CAGRincreasing
+11.3%
2014 → 2024
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2024Latest
Diluted Shares: 110,025
105,163
+23.50%
FY 2023
Diluted Shares: 85,141
85,149
-0.02%
FY 2022
Diluted Shares: 85,142
85,169
+2.46%
FY 2021
Diluted Shares: 96,179
83,124
+3.46%
FY 2020
Diluted Shares: 80,344
80,344
+0.00%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs XTLB
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+>999%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+>999%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+>999%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+>999%
#7
XTL Biopharmaceuticals Ltd.XTLB
XTL Biopharmaceuticals Ltd.YOU
105,163—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

XTL Biopharmaceuticals Ltd. (XTLB) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2024, XTL Biopharmaceuticals Ltd. reports 105,163 basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

XTL Biopharmaceuticals Ltd.'s basic shares outstanding (105,163) represents currently issued shares. Diluted shares outstanding (110,025) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +4.62%.

Shares Outstanding vs. Float (Free Float)

XTL Biopharmaceuticals Ltd.'s float is 2.3M (97.5% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float2.3M(97.5%)
Outstanding2.4M

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

XTL Biopharmaceuticals Ltd. (XTLB) shares outstanding history from 2005 to 2024. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

XTL Biopharmaceuticals Ltd. shares outstanding for the fiscal year ending December 31, 2024 were 105,163, a 23.50% increase year-over-year. XTL Biopharmaceuticals Ltd. FY 2024 shares outstanding were 105,163, a +23.50% increase from FY 2023.

XTL Biopharmaceuticals Ltd. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of +11.3% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

XTLB shares outstanding · 4 questions

As of December 31, 2024, XTL Biopharmaceuticals Ltd. (XTLB) has approximately 105,163 basic shares outstanding and 110,025 diluted shares outstanding. This represents a +23.50% year-over-year increase from FY 2023 (85,149). The increase may reflect equity compensation issuances or secondary offerings.

XTLB shares outstandinghow many shares does XTLB haveXTLB basic shares 2024XTLB diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · XTL Biopharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09